Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: BendamustineDrug: Brentuximab VedotinDrug: CarboplatinProcedure: Computed TomographyDrug: EtoposideDrug: GemcitabineDrug: IfosfamideDrug: Pegylated Liposomal Doxorubicin HydrochlorideProcedure: Positron Emission TomographyBiological: PembrolizumabRadiation: Radiation TherapyOther: Transplant ConditioningDrug: Vinorelbine
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05711628
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 45
- Registration Number
- NCT05603013
- Locations
- 🇨🇳
Second Affiliated Hospital of Soochow University, Suzhou, China
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 49
- Registration Number
- NCT05583110
- Locations
- 🇪🇸
Complejo hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Las Palmas, Spain
🇪🇸Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Costa del Sol, Málaga, Andalucía, Spain
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Drug: AlectinibDrug: AlpelisibDrug: AnastrozoleBiological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionDrug: CapecitabineDrug: CarboplatinDrug: CobimetinibDrug: EntrectinibDrug: EribulinDrug: FulvestrantBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabDrug: IrinotecanDrug: LetrozoleDrug: Nab-paclitaxelDrug: NiraparibDrug: OlaparibDrug: PaclitaxelDrug: PalbociclibBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab EmtansineDrug: VemurafenibDrug: VinorelbineDrug: Vismodegib
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 732
- Registration Number
- NCT05104866
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 27
- Registration Number
- NCT05063786
- Locations
- 🇪🇸
Hospital Galdakao-Usansolo, Bilbao, Spain
🇦🇹Ordensklinikum Linz GmbH - BHS, Linz, Austria
🇦🇹Pyhrn - Eisenwurzen Klinikum Steyr, Steyr, Austria
Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Zhiyong Yu
- Target Recruit Count
- 100
- Registration Number
- NCT04963595
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT04943627
- Locations
- 🇦🇲
Hematology Center after prof. R. Yeolyan, Yerevan, Armenia
🇦🇲National Center of Oncology named after V.A. Fanarjian, Yerevan, Armenia
🇺🇸Optimum Research (Southwest Women's Oncology Center), Albuquerque, New Mexico, United States
Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2022-04-07
- Target Recruit Count
- 30
- Registration Number
- NCT04903652
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04745975
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.